Back to search

National and Kapodistrian University of Athens

Βιοδείκτες οξείας νεφρικής βλάβης σε ασθενείς της μονάδας εντατικής θεραπείας

Abstract

dc:description

INTRODUCTION: Despite the technological and pharmaceutical advances made during the last decades, both incidence and mortality associated with acute kidney injury (AKI) in the critically ill patients remain unchanged. Serum creatinine (sCr), which is the primary biomarker of renal dysfunction in use to date, has many disadvantages, such as the time delay in its increase in the serum, and the influence of other factors on its level. Hence, there is a need for identification of better renal biomarkers in order to provide timely intervention for prevention and treatment of acute kidney damage. Two such promising biomarkers are neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C (CysC).PURPOSE: To compare the predictive abilities of admission pNGAL, pCysC, uNGAL, sCr and their combinations for the prediction of the following outcomes: a) Primary outcome: AKI development within 7 days post-ICU admission b) Secondary outcomes: renal replacement therapy need during ICU stay and ICU mortality. Moreover, the predictive ability of the peak value of pNGAL, pCysC and sCr for the aforementioned outcomes will be estimated.METHODS: This was a prospective observational study of adult patients admitted to a 30-bed general Academic Critical Care Department of ‘Evangelismos’ General Hospital of Athens. All consecutive patients admitted to the ICU were screened for eligibility. Exclusion criteria were the following: End stage renal disease, known chronic kidney disease or nephrectomy or renal transplantation, expected ICU stay or imminent death in less than 48 h, transfer from another ICU or HDU, brain death, age < 18 years, inability to draw blood or urine (anuria). The lowest sCr level found within 12 months prior to ICU admission was used as baseline. If it was not available, then the lowest of the on-admission sCr or final ICU sCr was used. AKI was defined according to RIFLE classification. Demographics, co-morbidities, admission diagnosis, outcome measures, disease severity scores and routine laboratory data were recorded on a daily basis. Blood samples for pNGAL, pCysC, sCr and urine sample for uNGAL were collected within 1 h, at the latest, of enrolment. In addition to that, blood samples were obtained 24 and 48 h after admission for pNGAL, pCysC and sCr. pNGAL was measured by Triage® NGAL test, pCysC by MNII nephelometer, while uNGAL by the ARCHITECT platform. Statistical analysis: the following tests were used: multiple logistic regression, ROC analysis, DeLong test for AUCs comparison, Youden’s test, log-rank-test and Cox regression analysis. Furthermore, we quantified the improvement of biomarkers and their combinations on AKI risk prediction with modern statistical methods, such as the category-free net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indices.RESULTS: Of the 100 patients enrolled, 36 developed AKI within 7 days, 10 needed renal replacement therapy during ICU stay, while the ICU mortality rate was 33%. Both pNGAL and pCysC levels increased earlier than sCr levels in the AKI group. All three novel biomarkers and sCr had moderate predictive ability for AKI occurrence and none of them had significantly higher AUC over the others. The vast majority of their combinations had higher AUCs than that of each biomarker alone, but only two of these biomarker combinations (pNGAL+sCr and pNGAL+uNGAL+sCr) reached statistical significance (p<0.05 vs sCr) and were selected to participate in the subsequent analyses. Both combinations had better specificities, positive likelihood ratios (+) LR) and positive predictive values (PPV) than those of any individual biomarker. We then developed the most efficient reference clinical model for AKI prediction, which included SAPS III and INR, using multivariate logistic regression with stepwise backward elimination. The AUC of this model was 0.756. Each biomarker was then added to the reference model to assess improvement in the predictive ability of the model. Of the individual biomarkers, only the addition of pNGAL to the model increased the AUC significantly from 0.756 to 0.852 (p=0.03). Moreover, the addition of pNGAL to the reference model improved its predictive ability, as measured by the category-free NRI (0.78, p=0.0002) and IDI (0.16, p=0.0004) indices, more than each of the other three biomarkers did. Next, we followed the same procedure with the two biomarker combinations. Both of them, when added to the reference model, increased its AUC significantly and slightly more than pNGAL did (0.858, p=0.04); their NRI was equal to that of pNGAL (0.78, p=0.0002), but higher than that of the other three biomarkers, whereas their IDI was higher than that of each individual biomarker (0.23, p=0.0001). With regard to the predictive capacity for renal replacement therapy need during ICU stay, the AUCs of pNGAL, pCysC, uNGAL, sCr and their best combination (pNGAL+uNGAL+sCr) were 0.75 (95% CI: 0.65-0.83), 0.79 (95% CI: 0.69-0.86), 0.78 (95% CI: 0.68-0.85), 0.77 (95% CI: 0.67-0.85) and 0.82 (95% CI: 0.66-0.98), respectively. Moreover, all admission individual biomarkers and their combinations had moderate performance for death prediction during ICU stay. Cox proportional hazards model revealed that uNGAL was the only independently associated biomarker with ICU mortality (HR: 2.9, p<0.01). Finally, a model including the peak values of the above biomarkers had very good AUC (0.90, 95% CI: 0.81−0.98) for AKI prediction 7 days after ICU admission.CONCLUSIONS: Both pNGAL and pCysC levels increased earlier than sCr levels in the AKI group. When we evaluated the predictive ability for AKI occurrence only by means of AUC, then none of the three novel biomarkers was superior to each other or to sCr, while the two combinations were better than sCr. However, when we assessed the predictive performance with modern indices of reclassification improvement, namely the category-free NRI and the IDI, the two combinations were superior not only to sCr, but also to the other three novel biomarkers. Moreover, pNGAL was superior to the other three. Early AKI detection by a combination of renal biomarkers could lead to timely interventions (e.g. avoidance of nephrotoxic drugs, early renal replacement therapy initiation) to prevent the detrimental effects of AKI in critically ill patients.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kokkoris, Stylianos
  • Κόκκορης, Στυλιανός

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40274

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kokkoris, Stylianos; Κόκκορης, Στυλιανός. Βιοδείκτες οξείας νεφρικής βλάβης σε ασθενείς της μονάδας εντατικής θεραπείας. National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/40274